TP53 and cancer: Genomic disruption is the driver of BE progression. Increasing number of deletions (p < 0.01) and amplifications (p < 0.001) from BE to EACHomozygous CDKN2A deletion (with p53 loss) in 4/11 BETP53 mutations determined in early cancers followed by genomic doubling